Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Di Giacomo A, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P. Valpione S, et al. Among authors: di giacomo a. Eur J Cancer. 2018 Mar;91:116-124. doi: 10.1016/j.ejca.2017.12.007. Epub 2018 Jan 19. Eur J Cancer. 2018. PMID: 29360604 Free article.
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).
Di Giacomo AM, Danielli R, Calabrò L, Bertocci E, Nannicini C, Giannarelli D, Balestrazzi A, Vigni F, Riversi V, Miracco C, Biagioli M, Altomonte M, Maio M. Di Giacomo AM, et al. Cancer Immunol Immunother. 2011 Apr;60(4):467-77. doi: 10.1007/s00262-010-0958-2. Epub 2010 Dec 18. Cancer Immunol Immunother. 2011. PMID: 21170646 Free PMC article. Clinical Trial.
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis.
Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries IJ, Sucker A, Schadendorf D, Büttner P, Garbe C, Pawelec G. Weide B, et al. Among authors: di giacomo am. J Clin Oncol. 2012 May 20;30(15):1835-41. doi: 10.1200/JCO.2011.40.2271. Epub 2012 Apr 23. J Clin Oncol. 2012. PMID: 22529253
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, Fonsatti E, Annesi D, Queirolo P, Testori A, Ridolfi R, Parmiani G, Maio M. Di Giacomo AM, et al. Lancet Oncol. 2012 Sep;13(9):879-86. doi: 10.1016/S1470-2045(12)70324-8. Epub 2012 Aug 13. Lancet Oncol. 2012. PMID: 22894884 Clinical Trial.
The cost of unresectable stage III or stage IV melanoma in Italy.
Maio M, Ascierto P, Testori A, Ridolfi R, Bajetta E, Queirolo P, Guida M, Romanini A, Chiarion-Sileni V, Pigozzo J, Di Giacomo AM, Calandriello M, Didoni G, van Baardewijk M, Konto C, Lucioni C. Maio M, et al. Among authors: di giacomo am. J Exp Clin Cancer Res. 2012 Nov 1;31(1):91. doi: 10.1186/1756-9966-31-91. J Exp Clin Cancer Res. 2012. PMID: 23116062 Free PMC article.
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells.
Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM, Maio M, Sucker A, Schilling B, Schadendorf D, Büttner P, Garbe C, Pawelec G. Weide B, et al. Among authors: di giacomo am. Clin Cancer Res. 2014 Mar 15;20(6):1601-9. doi: 10.1158/1078-0432.CCR-13-2508. Epub 2013 Dec 9. Clin Cancer Res. 2014. PMID: 24323899
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases.
Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A, Del Vecchio M, Di Guardo L, Maio M, Di Giacomo AM, Antonuzzo A, Cognetti F, Ferraresi V, Ridolfi L, Guidoboni M, Guida M, Pigozzo J, Chiarion Sileni V. Queirolo P, et al. Among authors: di guardo l, di giacomo am. J Neurooncol. 2014 May;118(1):109-16. doi: 10.1007/s11060-014-1400-y. Epub 2014 Feb 16. J Neurooncol. 2014. PMID: 24532241 Free PMC article.
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Di Giacomo AM, Maio M, Schilling B, Sucker A, Schadendorf D, Hassel JC, Eigentler TK, Martus P, Wolchok JD, Blank C, Pawelec G, Garbe C, Weide B. Martens A, et al. Among authors: di giacomo am. Clin Cancer Res. 2016 Jun 15;22(12):2908-18. doi: 10.1158/1078-0432.CCR-15-2412. Epub 2016 Jan 19. Clin Cancer Res. 2016. PMID: 26787752 Free PMC article.
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.
Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kähler K, Heinzerling L, Gutzmer R, Bender A, Gebhardt C, Romano E, Meier F, Martus P, Maio M, Blank C, Schadendorf D, Dummer R, Ascierto PA, Hospers G, Garbe C, Wolchok JD. Weide B, et al. Among authors: di giacomo am. Clin Cancer Res. 2016 Nov 15;22(22):5487-5496. doi: 10.1158/1078-0432.CCR-16-0127. Epub 2016 May 16. Clin Cancer Res. 2016. PMID: 27185375 Free PMC article.
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, Larkin J. Ascierto PA, et al. Among authors: di giacomo am. Lancet Oncol. 2016 Sep;17(9):1248-60. doi: 10.1016/S1470-2045(16)30122-X. Epub 2016 Jul 30. Lancet Oncol. 2016. PMID: 27480103 Clinical Trial.
220 results